BGE-102 advances in Phase II for CV and retinal diseases
BIOA says its NLRP3 inhibitor BGE-102 is advancing in Phase II for cardiovascular and retinal diseases, with key efficacy data expected next year.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.